Salvianolic Acid B Protects Against Paraquat-induced Pulmonary Injury by Mediating Nrf2/Nox4 Redox Balance and TGF-β1/Smad3 Signaling
Overview
Toxicology
Affiliations
The present study was aimed at exploring the protective effects of Salvianolic acid B (SalB) against paraquat (PQ)-induced lung injury in mice. Lung fibrotic injuries were induced in mice by a single intragastrical administration of 300mg/kg PQ, then the mice were administrated with 200mg/kg, 400mg/kg SalB, 100mg/kg vitamin C (Vit C) and dexamethasone (DXM) for 14days. PQ-triggered structure distortion, collagen overproduction, excessive inflammatory infiltration, pro-inflammatory cytokine release, and oxidative stress damages in lung tissues and mortality of mice were attenuated by SalB in a dose-dependent manner. Furthermore, SalB was noted to enhance the expression and nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) and reduce expression of the reactive oxygen species-generating enzyme Nox4 [NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase-4]. SalB also inhibited the increasing expression of transforming growth factor (TGF)-β1 and the phosphorylation of its downstream target Smad3 which were enhanced by PQ. These results suggest that SalB may exert protective effects against PQ-induced lung injury and pulmonary fibrosis. Its mechanisms involve the mediation of Nrf2/Nox4 redox balance and TGF-β1/Smad3 signaling.
Rong Y, Zhu M, Wang N, Zhang F, Liu T Front Pharmacol. 2025; 15():1539363.
PMID: 39845801 PMC: 11750845. DOI: 10.3389/fphar.2024.1539363.
Li X, Li J, Zeng W, Wang B, Du M, Liang L Front Pharmacol. 2024; 15:1384418.
PMID: 38983912 PMC: 11231192. DOI: 10.3389/fphar.2024.1384418.
Monomeric compounds from natural products for the treatment of pulmonary fibrosis: a review.
Li Z, Yang Y, Gao F Inflammopharmacology. 2024; 32(4):2203-2217.
PMID: 38724690 DOI: 10.1007/s10787-024-01485-0.
Lian C, Wang R, Wang J, Wang Z, Zhang W, Wang L Vet Res Commun. 2022; 47(2):651-661.
PMID: 36261742 DOI: 10.1007/s11259-022-10021-w.
Elebeedy D, Elkhatib W, Kandeil A, Ghanem A, Kutkat O, Alnajjar R RSC Adv. 2022; 11(47):29267-29286.
PMID: 35492070 PMC: 9040650. DOI: 10.1039/d1ra05268c.